<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<!-- saved from url=(0159)http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll/BMJSPLITCE/cvd.html/0205/0205_q7/0205_i16?f=templates&fn=document-frame.htm&q=hypertension&x=Simple&2.0 -->
<HTML><HEAD><TITLE>Diuretics and Hypertension 92101 Text</TITLE>
<META http-equiv=Content-Type content="text/html; charset=windows-1252"><LINK 
href="0205_i16_files/bmj.css" type=text/css rel=stylesheet>
<META content="MSHTML 5.50.4807.2300" name=GENERATOR></HEAD>
<BODY topMargin=0>
<TABLE cellSpacing=0 borderColorDark=#ffffff cellPadding=0 width="100%" 
borderColorLight=#c2c2c2 border=1>
  <TBODY>
  <TR>
    <TD class=heading id=heading>
      <SCRIPT src="0205_i16_files/0205_i16.0"></SCRIPT>

      <SCRIPT language=JavaScript> function showWindow(targeturl) { window.open(targeturl, ""); } </SCRIPT>

      <TABLE width="100%" border=0>
        <TBODY>
        <TR>
          <TD align=right><SPAN class=localheadtopic 
            id=localheadtopic><SECTION>Cardiovascular 
            disorders</SECTION></SPAN><IMG height=10 
            src="0205_i16_files/spacer.gif" width=10 align=absMiddle 
            border=0><BR><SPAN class=localhead id=localhead><TOPIC>Primary 
            prevention</TOPIC><IMG height=10 src="0205_i16_files/spacer.gif" 
            width=10 align=absMiddle border=0></SPAN></TD></TR>
        <TR>
          <TD class=title-author id=title-author vAlign=top noWrap align=right 
          bgColor=#ffffff height=30>Clinical Evidence writers on primary prevention<IMG height=10 
            src="0205_i16_files/spacer.gif" width=10 align=absMiddle 
        border=0></TD>
        </TR></TBODY></TABLE><BR>
      <H1 
      style="DISPLAY: none; FONT-SIZE: 0pt; VISIBILITY: hidden">Antihypertensive 
      drugs</H1>
      <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
        <TBODY>
        <TR>
          <TD class=question id=question vAlign=top width="10%"><B><SPAN 
            class=question-title id=question-title>QUESTION</SPAN></B></TD>
          <TD class=question id=question bgcolor="#CCCCCC">&nbsp;<B>What are the 
            effects of drug treatment in primary hypertension</B><SPAN 
            style="FONT-WEIGHT: bold; BACKGROUND: #ffffff"></SPAN><B>?</B></TD>
        </TR></TBODY></TABLE><BR><A 
      name=I16>
      <H2 style="DISPLAY: none; FONT-SIZE: 0pt; VISIBILITY: hidden">Comparing 
      antihypertensives</H2>
      <TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
        <TBODY>
        <TR class=option id=option>
          <TD class=option id=option style="PADDING-LEFT: 2px" vAlign=top 
          width="10%"><SPAN class=option-title 
            id=option-title>OPTION&nbsp;&nbsp;&nbsp;</SPAN></TD>
          <TD class=option id=option style="PADDING-LEFT: 2px" 
            width="100%"><B>Comparing antihypertensive drug 
        treatments</B></TD></TR></TBODY></TABLE></A>
      <TABLE cellSpacing=0 cellPadding=0 width="100%" border=0>
        <TBODY>
        <TR>
          <TD><A name=I16-SUMSTATEMENT><B>
            <P style="MARGIN-LEFT: 3px" align=justify><IMG 
            alt="substantive change" src="0205_i16_files/smalrght.gif" 
            border=0>Two systematic reviews have found that initial treatment 
              with diuretics, ACE inhibitors, or ß blockers reduces mortality 
              and morbidity, with minimal adverse effects. RCTs found no significant 
              morbidity or mortality differences among these agents. We found 
              limited evidence from one systematic review of RCTs that diuretics, 
              ß blockers, and ACE inhibitors reduced coronary heart disease and 
              heart failure more than calcium channel antagonists. One RCT has 
              found that a thiazide diuretic is superior to an &#945; blocker 
              in reducing cardiovascular events, particularly congestive heart 
              failure.<IMG 
            alt="substantive change" src="0205_i16_files/smalleft.gif" 
            border=0></P>
            </B></A></TD></TR></TBODY></TABLE><BR>
      <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
        <TBODY>
        <TR>
          <TD>
            <P align=justify><FONT color=#0033cc><A 
            name=I16-BENEFITS><B>Benefits: </B></A></FONT><B><font color="#FF0000">ß 
              Blockers versus diuretics: </font></B><font color="#FF0000">One 
              systematic review (search date 1995, &gt;&nbsp;48&nbsp;000 people) 
              identified RCTs comparing effects of high and low dose diuretics 
              versus ß blockers. <A 
            href="#references">[128]</A> A second systematic review (search date 
              1998) was limited to 10 RCTs in 16&nbsp;164 elderly people. <A 
            href="#references">[129]</A> These reviews did not summarise direct 
              comparisons of diuretics versus ß blockers but compared results 
              of trials that used diuretics as first line agents versus results 
              of trials that used ß blockers as first line agents. The reviews 
              found no significant difference between diuretics and ß blockers 
              for lowering blood pressure. They found that diuretics reduced coronary 
              events, but found no evidence that ß blockers reduced coronary events.</font> 
              <B>ß Blockers versus ACE inhibitors: </B>One single blind RCT (10&nbsp;985 
              people, aged 25–66 years) found that an ACE inhibitor (captopril) 
              was no more effective than conventional treatment (diuretics or 
              ß blockers) in reducing cardiovascular morbidity or mortality. Captopril 
              increased the risk of stroke compared with ß blockers (125 people 
              would need to be treated with ACE inhibitor rather than ß blocker 
              for one extra stroke to occur, 95% CI 69 to 651 people). However, 
              the methods of the trial may limit the validity of results (see 
              comment below). <A 
            href="#references">[130]</A> <B>Comparison of ß blockers, diuretics, 
              ACE inhibitors, and calcium channel antagonists: </B>One unblinded 
              RCT (6600 people, aged 70–84 years) compared diuretics, ß blockers, 
              or both, versus calcium channel antagonists (felodipine or isradipine) 
              versus ACE inhibitors (enalapril or lisinopril). It found no significant 
              difference in blood pressure control or cardiovascular morbidity 
              or mortality. <A 
            href="#references">[131]</A> <IMG 
            alt="substantive change" src="0205_i16_files/smalrght.gif" 
            border=0>One systematic review (search date 2000, 8 RCTs) compared 
              different antihypertensive regimens, and found no significant differences 
              in outcome among people initially treated with ß blockers, diuretics, 
              or ACE inhibitors. <A 
            href="#references">[132]</A> However, it found that ß blockers or 
              diuretics decreased coronary events compared with calcium channel 
              antagonists, and increased stroke rate, although there was no significant 
              difference for all cause mortality (OR for mortality, ß blockers 
              or diuretics <EM>v</EM> calcium antagonists 1.01, 95% CI 0.92 to 
              1.11). ACE inhibitors did not significantly alter all cause mortality 
              or stroke rate compared with calcium channel antagonists, but decreased 
              coronary events (OR for ACE inhibitor <EM>v</EM> calcium antagonist 
              1.03, 95% CI 0.91 to 1.18 for all cause mortality; 1.02, 95% CI 
              0.85 to 1.21 for stroke; 0.81, 95% CI 0.68 to 0.97 for coronary 
              events). <A 
            href="#references">[132]</A> <IMG 
            alt="substantive change" src="0205_i16_files/smalleft.gif" 
            border=0><B> Comparison of &#945; blockers and diuretics:</B> A double 
              blind RCT (335 high risk people with hypertension) found no differences 
              in coronary heart disease outcomes between doxazosin, an &#945; 
              blocker, compared with chlorthalidone. However, doxazosin compared 
              with chlorthalidone increased the total number of cardiovascular 
              events (4 year rate 25% <EM>v</EM> 22%; HR 1.25, 95% CI 1.17 to 
              1.33) and, in particular, increased congestive heart failure (4 
              year rate 8% <EM>v</EM> 4%; HR 2.04, 95% CI 1.79 to 2.32). <A 
            href="#references">[133]</A> <B>Drug treatment in people with diabetes: 
              </B><A 
            href="http://www.clinicalevidenceonline.org/lpBinCE/lpext.dll?f=id&amp;id=0601&amp;t=document-frame.htm&amp;2.0&amp;p=">See 
              cardiovascular disease in diabetes</A>.</P>
          </TD></TR></TBODY></TABLE>
      <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
        <TBODY>
        <TR>
          <TD>
            <P align=justify><FONT color=#0033cc><A name=I16-HARMS><B>Harms: </B></A></FONT><B><font color="#FF0000">Quality 
              of life and tolerability:</font></B><font color="#FF0000"> In the 
              three long term, double blind comparisons of low dose diuretics, 
              ß blockers, ACE inhibitors, and calcium channel blockers, tolerability 
              and overall quality of life indicators tended to be more favourable 
              for diuretics and ß blockers than for newer drugs. <A 
            href="#references">[134]</A> <A 
            href="#references">[135]</A> <A 
            href="#references">[136]</A> One systematic review (search date 1998) 
              of RCTs comparing thiazides versus ß blockers found that thiazides 
              were associated with fewer withdrawals because of adverse effects 
              (RR 0.69, 95% CI 0.63 to 0.76).</font> <A 
            href="#references">[137]</A> Adverse effects are agent specific. The 
              recent unblinded RCT comparing diuretics, ß blockers, calcium channel 
              antagonists, and ACE inhibitors found that after 5 years of follow 
              up, 26% of people receiving felodipine or isradipine reported ankle 
              oedema, 30% receiving enalapril or lisonopril reported cough, and 
              9% receiving diuretics and/or ß blockers reported cold hands and 
              feet. <A 
            href="#references">[131]</A> <B>Major harm controversies:</B> Case 
              control, cohort, and randomised studies suggest that short and intermediate 
              acting dihydropyridine calcium channel blockers, such as nifedipine 
              and isradipine, may increase cardiovascular morbidity and mortality. 
              <A 
            href="#references">[138]</A> </P>
          </TD></TR></TBODY></TABLE>
      <TABLE cellSpacing=0 cellPadding=3 width="100%" border=0>
        <TBODY>
        <TR>
          <TD>
            <P align=justify><FONT color=#0033cc><A name=I16-COMMENT><B>Comment: 
              </B></A></FONT>Results of the large ACE inhibitor trial reported 
              above warrant cautious interpretation because a flaw in the randomisation 
              process resulted in unbalanced groups. <A 
            href="#references">[130]</A> </P>
          </TD></TR></TBODY></TABLE><BR><A name=references></A>
      <TABLE cellSpacing=0 cellPadding=0 border=0>
        <TBODY>
        <TR>
          <TD width=90 bgColor=#404040><IMG height=2 src="" width=1 
            align=absMiddle border=0></TD>
          <TD vAlign=bottom width="100%" bgColor=#404040><IMG height=2 src="" 
            width=1 align=absMiddle border=0></TD></TR>
        <TR>
          <TD class=key-message id=key-message width=90 
            bgColor=#404040><B>References</B></TD>
          <TD width="100%">&nbsp;</TD></TR></TBODY></TABLE><BR>
      <TABLE cellPadding=2 width="100%" align=center>
        <TBODY>
        <TR><A class=reference id=reference name=REF128></a>
          <TD class=reference id=reference vAlign=top width=15>128. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Psaty BM, Smith 
            NS, Siscovick DS, et al. Health outcomes associated with antihypertensive 
            therapies used as first line agents: a systematic review and meta-analysis. 
            <EM>JAMA</EM> 1997;277:739–745. Search date 1995; primary source Medline.</TD>
        </TR>
        <TR><A class=reference id=reference name=REF129></a>
          <TD class=reference id=reference vAlign=top width=15>129. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Messerli FH, 
            Grossman E, Goldbourt. Are beta blockers efficacious as first-line 
            therapy for  hypertension 
            in the elderly? A systematic review. <EM>JAMA</EM> 1998;279:1903–1907. 
            Search date 1998; primary source Medline.</TD>
        </TR>
        <TR><A class=reference id=reference name=REF130></a>
          <TD class=reference id=reference vAlign=top width=15>130. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Hansson L, 
            Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme 
            inhibition compared with conventional therapy on cardiovascular morbidity 
            and mortality in hypertension: the captopril prevention project (CAPP) randomised trial. <EM>Lancet</EM> 
            1999;353:611–616. </TD>
        </TR>
        <TR><A class=reference id=reference name=REF131></a>
          <TD class=reference id=reference vAlign=top width=15>131. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Hansson L, 
            Lindholm L, Ekbom T, et al. Randomised trial of old and new antihypertensive 
            drugs in elderly patients: cardiovascular mortality and morbidity 
            the Swedish trial in old patients with hypertension-2 study. <EM>Lancet</EM> 
            1999;354:1751–1756. </TD>
        </TR>
        <TR><A class=reference id=reference name=REF132></a>
          <TD class=reference id=reference vAlign=top width=15>132. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Blood Pressure 
            Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, 
            calcium antagonists, and other blood-pressure-lowering drugs: results 
            of prospectively designed overviews of trials. <EM>Lancet</EM> 2000;356:1955–1964. 
            Search date July 2000; primary sources WHO-International Society of Hypertension registry of randomised trials; trials were sought that had not published 
            or presented their results before July 1995.</TD>
        </TR>
        <TR><A class=reference id=reference name=REF133></a>
          <TD class=reference id=reference vAlign=top width=15>133. </TD>
          <TD class=reference id=reference vAlign=top width="100%">The ALLHAT 
            Officers and Coordinators for the ALLHAT Collaborative Research Group. 
            Major cardiovascular events in hypertensive patients randomized to 
            doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering 
            treatment to prevent heart attack trial (ALLHAT). <EM>JAMA</EM> 2000;283:1967–1975. 
          </TD>
        </TR>
        <TR><A class=reference id=reference name=REF134></a>
          <TD class=reference id=reference vAlign=top width=15>134. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Neaton JD, 
            Grimm RH, Prineas RJ, et al. Treatment of mild hypertension 
            study: final results. <EM>JAMA</EM> 1993;270:713–724. </TD>
        </TR>
        <TR><A class=reference id=reference name=REF135></a>
          <TD class=reference id=reference vAlign=top width=15>135. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Materson BJ, 
            Reda DJ, Cushman WC, et al. Single drug therapy for hypertension in men. <EM>N Engl J Med</EM> 1993;328:914–921. </TD>
        </TR>
        <TR><A class=reference id=reference name=REF136></a>
          <TD class=reference id=reference vAlign=top width=15>136. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Philipp T, 
            Anlauf M, Distler A, Holzgreve H, Michaelis J, Wellek S. Randomised, 
            double blind, multicentre comparison of hydrochlorothiazide, atenolol, 
            nitrendipine, and enalapril in antihypertensive treatment: results 
            of the HANE study. <EM>BMJ</EM> 1997;315:154–159.</TD>
        </TR>
        <TR><A class=reference id=reference name=REF137></a>
          <TD class=reference id=reference vAlign=top width=15>137. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Wright JM, 
            Lee CH, Chambers CK. Systematic review of antihypertensive 
            therapies: does the evidence assist in choosing a first line drug? 
            <EM>Can Med Assoc J</EM> 1999;161:25–32. Search date 1998; primary 
            sources Medline 1996 to 1997, Cochrane Library to 1998.</TD></TR>
        <TR><A class=reference id=reference name=REF138></a>
          <TD class=reference id=reference vAlign=top width=15>138. </TD>
          <TD class=reference id=reference vAlign=top width="100%">Cutler JA. 
            Calcium channel blockers for hypertension&nbsp;—&nbsp;uncertainty 
            continues. <EM>N Engl J Med</EM> 1998;338:679–680. </TD>
        </TR></TBODY></TABLE>
      <TABLE width="100%" border=0>
        <TBODY>
        <TR>
          <TD vAlign=bottom width="50%">
          <TD align=right width="50%"><IMG 
            alt="BMJ - Clinical Evidence" src="../ce-bmj-small-banner%5B1%5D.gif" 
            border=0 width="89" height="44"></TD>
        </TR>
        <TR>
          <TD align=left width="50%"><SPAN 
            style="FONT-SIZE: 8pt; font-face: arial">Issue 5 - June 
          2001</SPAN></TD>
          <TD align=right width="50%"><SPAN 
            style="FONT-SIZE: 8pt; font-face: arial">© 2001 BMJ Publishing Group</SPAN></TD>
        </TR></TBODY></TABLE>
      <SCRIPT language=JavaScript>
			var purl = "0205.PDF"; 
</SCRIPT>
      </TD></TR></TBODY></TABLE>
<FORM name=LPHitCountForm><INPUT type=hidden value=8 name=LPHitCount> 
</FORM></BODY></HTML>
